Skye Bioscience, Inc. (SKYE) NASDAQ
0.77
+0.0438(+6.04%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.77
+0.0438(+6.04%)
Currency In USD
| Previous Close | 0.73 |
| Open | 0.77 |
| Day High | 0.77 |
| Day Low | 0.73 |
| 52-Week High | 5.75 |
| 52-Week Low | 0.57 |
| Volume | 89,632 |
| Average Volume | 513,247 |
| Market Cap | 27.03M |
| PE | -0.53 |
| EPS | -1.45 |
| Moving Average 50 Days | 0.77 |
| Moving Average 200 Days | 1.61 |
| Change | 0.04 |
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
GlobeNewswire Inc.
Mar 05, 2026 12:00 PM GMT
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conferen
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
GlobeNewswire Inc.
Feb 02, 2026 12:00 PM GMT
22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab dosesWeight regain during treatment interrupt
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
GlobeNewswire Inc.
Jan 29, 2026 12:00 PM GMT
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a post